CORD-19:2008f024274c53b0de1276f4047a6a641813fd98 / 133831-133947 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/2008f024274c53b0de1276f4047a6a641813fd98","sourcedb":"CORD-19","sourceid":"2008f024274c53b0de1276f4047a6a641813fd98","text":"HYB2055 was evaluated for its safety and immunopharmacology in a phase 1 clinical trial in healthy human volunteers.","tracks":[{"project":"CORD-19-Sentences","denotations":[{"id":"T86373","span":{"begin":0,"end":116},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"T86373","pred":"source","obj":"CORD-19-Sentences"}]},{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T326","span":{"begin":0,"end":116},"obj":"Sentence"}],"attributes":[{"subj":"T326","pred":"source","obj":"CORD-19_Custom_license_subset"}]},{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T1090","span":{"begin":8,"end":11},"obj":"Disease"}],"attributes":[{"id":"A1090","pred":"mondo_id","subj":"T1090","obj":"http://purl.obolibrary.org/obo/MONDO_0010518"},{"subj":"T1090","pred":"source","obj":"CORD-19-PD-MONDO"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19-Sentences","color":"#d6ec93","default":true},{"id":"CORD-19_Custom_license_subset","color":"#e893ec"},{"id":"CORD-19-PD-MONDO","color":"#93ecce"}]}]}}